Achilles On Getting ‘New Wave’ Immunotherapy From Concept To Clinic In Three Years

Clonal neoantigen immunotherapy developer Achilles Therapeutics tells the Pink Sheet how the regulatory landscape for advanced therapies might not be as tricky as it used to be.

Lab
Achilles is set to start testing its monoclonal neoantigen-based therapy in humans • Source: Shutterstock

More from R&D

More from Pink Sheet